ReviewCurrent urology reports2019
Combination Pharmacotherapy for Treatment of Overactive Bladder (OAB).
Review in Current urology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Article
- Association of Hemoglobin, albumin, lymphocyte, and platelet scores with the risk of overactive bladder syndrome in U.S. adults: A Nationwide cross-sectional study.Preventive medicine reports · 2025Article
- Ultrasound guided transabdominal botulinum toxin injection for refractory overactive bladder treatment.Scientific reports · 2025Article
- The relationship between physical activity and overactive bladder among American adults: a cross-sectional study from NHANES 2007-2018.Scientific reports · 2025Article
- Pharmacological treatment of pregnancy complications in adults: An overview of phase IV clinical trials.Medicine · 2025Review
- Genetic Variation inPharmaceutics · 2024Article
- The relationship between dietary live microbe intake and overactive bladder among American adults: a cross-sectional study from NHANES 2007-2018.Journal of health, population, and nutrition · 2024Article
- Diabetes mellitus, systemic inflammation and overactive bladder.Frontiers in endocrinology · 2024Article
- Relationship between alcohol use and overactive bladder disease: a cross-sectional study of the NHANES 2005-2016.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overactive bladder syndrome (OAB) negatively affects the quality of life of patients and their interactions with society. Treatment of OAB starts with behavioral modification and then pharmacotherapy using monotherapy with either antimuscarinics or β3 agonists. The third-line more invasive approaches are the next treatment option currently recommended. Both antimuscarinic agents and β3 agonists work through a different molecular pathway. This brings up the potential of having an additive effect when using a combination treatment for patients with OAB. Currently, the potential for using combination therapy to treat OAB in patients who had no improvement with a monotherapy approach before we attempt a more invasive approach is being explored. Several studies have shown the benefits of combination therapy which will be an additional option to the tools to treat OAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.